LEADER 01678cam a2200421Ii 4500001    9994629923506421
005    20231120133925.0
006    m     o  d f
007    cr b||||||||||
008    130606s2013    dcua    ob   f000 0 eng d
035    ocn846903715
035    (NjP)9462992-princetondb
035     |z(NjP)Voyager9462992
040    AZS |beng |erda |cAZS |dOCLCQ |dGPO |dMvI
043    n-us---
049    DOCS
074    0535-A-10 (online)
086 0  FT 1.37/2:317
090    Electronic Resource
100 1  Olson, Luke M., |eauthor.
245 14 The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period / |cLuke M. Olson, Brett W. Wendling.
264  1 Washington, DC : |bBureau of Economics, Federal Trade Commission, |c2013.
300    1 online resource (41 unnumbered pages) : |billustrations.
336    text |btxt |2rdacontent
337    computer |bc |2rdamedia
338    online resource |bcr |2rdacarrier
490 1  Working paper ; |vno. 317
500    Title from title screen (viewed on June 6, 2013).
500    "April 2013."
504    Includes bibliographical references.
650  0 Generic drugs |xEconomic aspects |zUnited States.
650  0 Generic drugs |xPrices |zUnited States.
650  0 Drugs |xPrices |zUnited States.
700 1  Wendling, Brett W., |eauthor.
710 1  United States. |bFederal Trade Commission. |bBureau of Economics, |eissuing body.
830  0 Working paper (United States. Federal Trade Commission. Bureau of Economics) ; |vno. 317.
945    DOCS |cFT 1.37/2:317
956 40  |uhttps://purl.fdlp.gov/GPO/gpo62909